The case for & against
Bull & Bear analysis
Bearish
Acurx Pharmaceuticals (NASDAQ: ACXP) is a biotechnology firm focused on developing innovative therapies to combat serious infections, particularly recurrent Clostridium difficile infections (CDI). Their flagship candidate, Ibezapolstat, targets both the treatment and prevention of CDI, positioning the company within the urgent healthcare theme of antibiotic resistance. Acurx operates in a competitive landscape, aiming to differentiate itself through its novel approaches to antibiotic development, including the preservation of gut microbiota.
Bull says
- ↑Ibezapolstat delivered 96% cure rate with no CDI recurrence in early trials.
- ↑Cash balance climbed to $10.7M in Q2 versus $7.6M year-end 2025, aiding funding.
- ↑Multiple patents granted for Ibezapolstat bolster IP moat against competitors.
- ↑Positive FDA feedback suggests a streamlined approval path pending phase III data.
- ↑High book-to-price ratio (1.85x) and growth factor signal undervaluation and upside.
- ↑Strong quality metrics and robust liquidity profile support operational stability.
Bear says
- ↓Reported Q2 net loss widened to $2.3M versus $2.2M year-ago, delaying breakeven.
- ↓R&D spend jumped 120% YoY to $1.1M, increasing cash burn before ASPIRE.
- ↓Ongoing need to raise capital for Phase III raises dilution and execution risk.
- ↓Entrenched CDI therapies like vancomycin may limit Ibezapolstat market adoption.
- ↓Weak profitability and negative earnings yield raise concerns on return generation.
- ↓High leverage risk and negative momentum point to potential downward pressure.
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-18-2026neutral
Transcript signals
Bull points
- The company ended the quarter with cash totaling $6.1 million, compared to $3.7 million, as of December 31, 2024, indicating an improvement in cash position.
- Research and development expenses for the three months ended June 30th were $.5 million, compared to $1.8 million for the three months ended June 30, 2024, a decrease of $1.3 million due primarily to a decrease in manufacturing costs and consulting costs, indicating better expense management.
- General and administrative expenses were $3.3 million versus $5.1 million for the six months ended June 30, 2024, a decrease of $1.8 million, indicating effective cost reductions.
Bear points
- net loss of $2.2 million or $1.89 per diluted share for the three months ended June 30, 2025, compared to a net loss of $4.1 million or $5.21 per diluted share for the three months ended June 30, 2024, showing ongoing challenges despite a smaller loss.
- net loss of $4.4 million or $4.01 per diluted share for the six months ended June 30, 2025, compared to a net loss of $8.5 million or $10.84 per diluted share for the six-month end of June 30, 2024, indicating persistent financial struggles.
- net loss of $2.2 million or $1.89 per diluted share for the three months ended June 30, 2025, compared to a net loss of $4.1 million or $5.21 per diluted share for the three months ended June 30, 2024,
Read full transcript analysis ›